SNAP

BIG 2-12

Share This Post

Schedules of Nab-Paclitaxel: evaluation of different schedules of nab-paclitaxel for metastatic breast cancer

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Toggle Content
Toggle Content

This trial is coordinated and sponsored by the International Breast Cancer Study Group (IBCSG) under the umbrella of the Breast International Group.

Pharmaceutical partner: Celgene

Toggle Content
Toggle Content
Toggle Content

Funding: Celgene grant

NCT01746225

More To Explore

PANACEA

Panacea BIG 4-13 PANACEA stands for anti-PD-1 monoclonAl aNtibody in AdvanCed, trastuzumab-resistant, HER2-positive breAst cancer. A phase Ib/II trial evaluating the efficacy of pembrolizumab and trastuzumab

Read More

DECRESCENDO

DECRESCENDO BIG 19-02 De-Escalation of adjuvant ChemotheRapy in HER2-positive, EStrogen reCEptor-negative, Node-negative early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER2 blOckade Share

Read More